Table 1.
Peptide sequences used in this study.
| Peptide name | Amino acid sequence (N to C) |
Binding affinity | Reference |
|---|---|---|---|
| LIR (derived from SQSTM1, SQSTM1332–346) | SGGDDDWTHLSSKEV | 3.2 µM to LC3B | [43] |
| mLIR | SGGDDDAAAASSKEV | ||
| ABP (derived from TMEM59, TMEM59263–281) | TAVEQYVPSEKLSIYGDLE | n.d. | [42] |
| mABP | TAVEQAVPSEKLSIAGDAE | ||
| SBP | MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP | 2.5–4.9 nM to streptavidin | [45] |
| QBP | SNWKWWPGIFD | 5.7 μM to Q62 | [46] |
| MTS1 (derived from TOMM20, TOMM201–34) | MVGRNSAIAAGVCGALFIGYCIYFDRKRRSDPNF | [47] | |
| MTS2 (derived from MFF, MFF323–342) | VMYSITVAFWLLNSWLWFRR | [48] | |
| MTS3 (derived from BCL2, BCL2218–239) | KTLLSLALVGACITLGAYLGHK | [49] | |
| MTS4 (derived from NLRX1, NLRX11–86) | MRWGHHLPRASWGSGFRRALQRPDDRIPFLIHWSWPLQGERPFGP PRAFIRHHGSSVDSAPPPGRHGRLFPSASATEAIQRHRRNL |
[50] |
Abbreviations: LIR, LC3-interacting region; ABP, ATG16L1-binding peptide; SBP, streptavidin-binding peptide; QBP, polyQ-binding peptide 1; MTS, mitochondria-targeting sequence. Bold letters represent positions where mutations were introduced. n.d., not determined.